Abbott, mAbxience Holdings Strike Biosimilars Commercialization Deal

Image Credit: Adobe Stock Images/ibreakstock

Abbott officially announced an agreement with mAbxience Holdings SL to commercialize several biosimilars focusing on oncology, women's health, and respiratory diseases in emerging markets. With the first molecules expected to launch in 2025, Abbott will register and commercialize the biosimilars, with mAbxience Holdings focusing on development, manufacturing, and supplying the necessary molecules. The partnership expands an existing agreement with mAbxience, initiated in Latin America in 2018.

"The expanded collaboration with mAbxience will complement our existing branded generic medicines portfolio with state-of-the-art biosimilars," said Daniel Salvadori,EVP, group president, established pharmaceuticals and nutritional products, Abbott. "With our large footprint in emerging countries and our commitment to put access and affordability at the center of what we do, this strategic collaboration will help more people in more places have access to affordable biosimilar medicines."

Reference: ABBOTT BROADENS ACCESS TO CUTTING-EDGE BIOSIMILARS IN KEY EMERGING MARKETS. Abbott. September 20, 2023. Accessed September 21, 2023. https://abbott.mediaroom.com/2023-09-20-Abbott-Broadens-Access-to-Cutting-Edge-Biosimilars-in-Key-Emerging-Markets